Angiodynamics Inc insider trading
Every open-market purchase and sale by Angiodynamics Inc's officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Angiodynamics Inc’s insiders pay?
From February 8, 2010 to October 30, 2026, 20 insiders reported 32 open-market purchases and 28 sales not made under a pre-set plan in Angiodynamics Inc. Twelve months after each purchase was reported, the shares were −8.6% against the S&P 500 on average (median −21.6%), over 32 purchases with a full year of prices; 34% beat the index. After sales, the shares moved −23.2% against the index over 12 months (a negative figure means selling was the right call). Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on February 9, 2010 into $15,851 by November 2, 2026, +2.8% a year. It held shares 70% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $67,427 (+12.1% a year), and held throughout $94,773 (+14.4%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Bucci Vincent | Director | 8 | −17.1% (8) | 25% | 0 | — | October 21, 2013 |
| Clemmer James C | President and CEO | 8 | +13.8% (8) | 50% | 0 | — | October 9, 2025 |
| Helsel Dave | SVP Global Operations and R&D | 0 | — | — | 5 | −52.4% (5) | February 1, 2023 |
| Devivo Joseph | President and CEO | 4 | −28.2% (4) | 0% | 0 | — | July 18, 2012 |
| Gould Kevin J | Director | 3 | −6.9% (3) | 33% | 1 | −67.8% (1) | July 18, 2019 |
| Greiner Charles R | VP - Global Franchise | 0 | — | — | 4 | −4.2% (4) | May 9, 2016 |
| Richard Stark | SVP, GM - Oncology | 0 | — | — | 4 | −14.0% (4) | November 17, 2017 |
| Trowbridge Stephen A | EVP and CFO | 2 | −50.9% (2) | 0% | 2 | +8.6% (1) | October 30, 2026 |
| Burgstahler David F | Director | 0 | — | — | 3 | −3.3% (3) | April 14, 2017 |
| Johnson Wesley | Director | 1 | −24.3% (1) | 0% | 2 | −26.1% (2) | April 13, 2022 |
| Donnelly Howard W | Director | 1 | +11.0% (1) | 100% | 1 | −10.6% (1) | July 21, 2017 |
| Kapusta Matthew C | SVP, Business Development | 2 | −14.7% (2) | 50% | 0 | — | April 16, 2014 |
| Nighan Warren Jr | SVP Quality and Regulatory | 0 | — | — | 2 | −26.6% (1) | July 31, 2026 |
| Campbell Chad Thomas | SVP/GM, Vascular Access | 0 | — | — | 1 | −24.3% (1) | October 6, 2021 |
| Centea Scott | Sr. VP/GM, Global VIT | 0 | — | — | 1 | −33.3% (1) | October 18, 2021 |
| Gold Jeffrey | Director | 1 | +17.1% (1) | 100% | 0 | — | November 13, 2012 |
| Greiner Michael | EVP and CFO | 0 | — | — | 1 | −43.4% (1) | November 8, 2018 |
| Meteny Dennis S | Director | 1 | +26.4% (1) | 100% | 0 | — | March 12, 2013 |
| Navilyst Medical Co-Invest, LLC | 10% owner | 0 | — | — | 1 | −9.4% (1) | August 5, 2016 |
| Weiss Lawrence T | SVP, Chief Legal Officer | 1 | −13.8% (1) | 0% | 0 | — | October 22, 2025 |
When several insiders traded Angiodynamics Inc
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Angiodynamics Inc in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 6 buying crowds with six months of prices, it averaged −14.6% against the index. After 1 selling crowd, −17.0%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| October 31, 2025 | 2 buying | −12.9% | −15.6% | not yet |
| October 31, 2022 | 2 buying | −12.0% | −45.0% | −66.8% |
| January 31, 2022 | 2 buying | +5.2% | +16.2% | −31.0% |
| October 29, 2021 | 3 selling | −22.7% | −17.0% | −36.1% |
| July 31, 2017 | 2 buying | +0.8% | −9.2% | +14.0% |
| January 31, 2013 | 2 buying | −24.4% | −15.7% | +9.0% |
| February 29, 2012 | 2 buying | −4.9% | −18.5% | −17.7% |